Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Two phase I open‐label studies were conducted to investigate the pharmacokinetics (PK), safety, and tolerability of single oral doses of selumetinib in subjects with end‐stage renal disease (ESRD) undergoing hemodialysis and subjects with varying degrees of hepatic impairment; both studies included...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Pharmacol
Main Authors: Dymond, Angela W., Martin, Paul, So, Karen, Huang, Yifan, Severin, Paul, Holmes, Victoria, Mariani, Gabriella, Marbury, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Special Populations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412920/
https://ncbi.nlm.nih.gov/pubmed/28019010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.848
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados